Genetic landscape and therapeutic evolution of cyclophosphamide: spotlight on breast cancer [0.03%]
环磷酰胺的基因组谱系和治疗演变：聚焦于乳腺癌研究
Jiaoyan Cao,Xin Xu,Tao Lu et al.
Jiaoyan Cao et al.
Cyclophosphamide is a chemotherapeutic agent widely used in breast cancer management. As a prodrug, its therapeutic efficacy and toxicity are profoundly influenced by host genetic variations that govern its metabolism, detoxification, DNA r...
RACGAP1 promotes the malignant phenotype and cisplatin resistance of nasopharyngeal carcinoma cells by upregulating HIF-1α [0.03%]
RACGAP1通过上调HIF-1α促进鼻咽癌细胞恶性表型和顺铂耐药性
Jiadi Dong,Yanghao Hu,Jingjing Chen et al.
Jiadi Dong et al.
Nasopharyngeal carcinoma (NPC) is a radiosensitive malignancy, but chemotherapy resistance remains a major challenge. This study investigated the role of RACGAP1, a GTPase regulator often overexpressed in cancers, in NPC progression and che...
Furmonertinib activity in NSCLC Harbouring EGFR L858R and ERBB2 S310F co-mutations: a case report with literature review [0.03%]
艾伏美替尼对EGFR L858R和ERBB2 S310F共突变非小细胞肺癌的疗效：一例报告及文献复习
Shiyue Liu,Runze Cao,Hong Li et al.
Shiyue Liu et al.
While targeted therapies have remarkably transformed the landscape of lung adenocarcinoma (LUAD) management, the clinical implications of concurrent mutations in EGFR and ERBB2 remain inadequately understood due to their exceptional rarity ...
Recent advances in polymer-based nanoparticles: current strategies and translational challenges in cancer therapy [0.03%]
基于聚合物的纳米颗粒近期在癌症治疗方面的进展：目前策略和转化挑战
Kumar Janakiraman,Vaidevi Sethuraman,Venkateshwaran Krishnaswami et al.
Kumar Janakiraman et al.
Polymer-based nanoparticles (PNPs) are emerging as a cornerstone in cancer therapy due to their ability to enhance drug solubility, improve pharmacokinetics and achieve precise tumor targeting. Nanoparticles, encompassing liposomes, dendrim...
Rethinking antibiotic use in hidradenitis suppurativa: a call for stewardship [0.03%]
重新思考汗腺炎中抗生素的使用：倡导管理规范
E Rosi,G Silvi,A Di Cesare et al.
E Rosi et al.
Thrice-weekly teicoplanin: an old drug for modern needs. Experience of its use as outpatient parenteral antibiotic therapy (OPAT) at infectious disease unit of Manzoni hospital (Lecco) [0.03%]
特拉杨定期三次给药：老药的新用途。马佐尼医院感染性疾病科特拉万用于门诊静脉注射抗生素治疗(OPAT)的经验
Valentina Morena,Federico Conti,Dario Cattaneo et al.
Valentina Morena et al.
Teicoplanin is a glycopeptide antibiotic with a long elimination half-life (50 hours) that allows administration thrice a week, though it is approved for daily use. The aim of this retrospective, single-arm study is to assess the clinical o...
Integrating immunotherapy into chemotherapy: real-world efficacy of GEMOX plus Tislelizumab in advanced gallbladder cancer [0.03%]
吉西他滨联合奥沙利铂(GEMOX)联合特瑞普利单抗治疗晚期胆囊癌的真实世界疗效分析
Daming Zhang,Yuchuan Liang,Jinbo Yang et al.
Daming Zhang et al.
This study aimed to evaluate the efficacy and prognostic factors of GEMOX (gemcitabine and oxaliplatin) combined with Tislelizumab in patients with advanced Gallbladder cancer (GBC). 150 patients with stage III-IV GBC were divided into two ...
Innovative sequential therapy in a rare case of refractory Erdheim-Chester disease with bilateral pulmonary involvement [0.03%]
复发性难治性Erdheim-Chester病伴双肺受累的创新序贯疗法在一例罕见病例中的应用
Zengyan Li,Zhiming Wu,Zelin Zhang et al.
Zengyan Li et al.
Background: Erdheim-Chester Disease (ECD) is a rare, multisystemic histiocytosis with complex diagnosis and management. Case Presentation: We report a case of a 44-year-old male with ECD,confirmed by lung biopsy, presenting with persistent ...
Initial cumulative area under the blood concentration-time curve of vancomycin is associated with the incidence of acute kidney injury [0.03%]
万古霉素早期累计曲线下面积与急性肾损伤发生率相关性研究
Yuta Ibe,Tomoyuki Ishigo,Satoshi Fujii et al.
Yuta Ibe et al.
We aimed to evaluate the relationship between the cumulative area under the concentration-time curve (AUC) for the first and second day of vancomycin (VCM) administration and acute kidney injury (AKI). The primary outcome was the cumulative...
E2F1-induced transcriptional activation of MAL2 inhibits sunitinib sensitivity and promotes the malignant progression of bladder cancer [0.03%]
E2F1诱导的MAL2转录激活抑制索拉非尼敏感性并促进膀胱癌恶性进展
Mingqiang Su,Wei Chen,Jingxian Luo et al.
Mingqiang Su et al.
Background: Mal, T cell differentiation protein 2 (MAL2) has emerged as a potential regulator in the progression of bladder cancer (BCa). Therapeutic resistance to sunitinib poses a significant challenge in BCa treatment....